Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Otsuka Ties Up With Mylan To Advance MDR-TB Drug In India?

Executive Summary

Otsuka, which has been under fire over delayed access to delamanid in India, appears to have allied with Mylan, which has now secured a key clearance for the novel multidrug-resistant TB therapy in the country.

You may also be interested in...

Mylan Gears To Make Otsuka’s MDR TB Drug In India

Manufacturing plans for multidrug-resistant tuberculosis (MDR-TB) drug Deltyba (delamanid) in India appear to be gathering steam, with partners Otsuka and Mylan commencing the technology transfer process for the product, although activists are concerned about the broader contours of the arrangement. Deltyba is also expected to be used in children and adolescents in India.

Call For India Compulsory Licenses For Last Resort TB Drugs

Public health campaigners in India and globally are pushing the government to allow Indian generic firms to make cheap copies of two new-generation, last resort antibiotics for drug-resistant tuberculosis through the use of patent-busting compulsory licenses. 

J&J’s India TB R&D Alliance – Can It Pull Off Something Special?

Johnson & Johnson’s tuberculosis R&D partnership with the Institute of Microbial Technology in India aims to develop shorter, simpler and safer TB regimens. The alliance has, at its forefront, an expert from the team that developed Sirturo (bedaquiline).

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts